© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
© 2020 MJH Life Sciences™ and . All rights reserved.
This slide deck covers the treatment of triple-negative breast cancer, a heterogeneous disease made up of numerous subtypes, and includes clinical variables that can help with prognosis and guide in treatment choice.
Triple-Negative Breast Cancer
Triple-Negative Breast Cancer by Subtype
What Are ER or PR “Borderline” Tumors?
TNBC and Treatment: What Do We Know?
Prognosis in TNBC
Drawing the Line: T1aN0 TNBC
(Neo)Adjuvant Chemotherapy Choices: Conventional Chemotherapy?
Are There Better Choices? Neoadjuvant Trials in TNBC
Local Recurrence and TNBC
CALOR Trial: Adjuvant Chemotherapy for Local Recurrence?
CALOR: Disease-Free Survival
BEATRICE: Adjuvant Bevacizumab
CALGB 40502 Subset Analyses
Later Lines of Therapy?
Eribulin vs Capecitabine
Olaparib in BRCA1/2 Carriers: Results
Breast Cancer, Ovarian Cancer, and PARPi
Targeting Heterogeneity of TNBC